Novartis has garnered significant attention from top investment firms, earning a 'Buy' rating from Goldman Sachs. Investment decisions by various groups show a mixed trend. Some groups have sold significant shares of Novartis AG (
NYSE:NVS), while others are hiking their stakes. Even though there was a slump in Novartis stock due to short of expected earnings, it bounced back, topping the market and outperforming expectations with the rise in the sale of blockbuster drugs. Encouraging trial data lends support for filing a new cancer drug. Furthermore, Novartis steadily increased its
earnings outlook on the back of profit and sales growth. It is also expanding its reach into cancer treatment, evidenced by acquiring cancer-focused MorphoSys and inking a deal with Voyager Therapeutics. However, it underwent some pressure due to weak sales of its prostate cancer drug and faced a lawsuit to block Maryland's new drug discount law. Simultaneously, the investment scenario portrayed a few red flags, with specific investors trimming their positions.
Novartis Stocks News Analytics from Fri, 18 Aug 2023 07:00:00 GMT to Sun, 02 Jun 2024 15:28:13 GMT -
Rating 6
- Innovation 4
- Information 9
- Rumor -6
